Wahidullah Noori, Pharm.D., M.S

Ascendis Pharma, Inc
Palo Alto, CA, United States

Disclosure information not submitted.

Presentation(s):

• SUN-770 - Palopegteriparatide Enhances Work Functioning and Productivity in Employed Adults with Chronic Hypoparathyroidism: 156-Week Results from the Pathway Trial

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT